Unum Therapeutics to Present at Upcoming Industry Conferences in September
September 05 2019 - 7:00AM
Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage
biopharmaceutical company focused on developing curative cell
therapies for cancer, today announced its participation in the
following industry conferences in September:
Cell & Gene Therapy Bioprocessing &
Commercialization, September 9 - 12, Boston, MA.
- Geoffrey Hodge, Chief Technical Officer at Unum Therapeutics,
will present "Designing the Cell Therapy Facility of the
Future by Learning from the Past" on Tuesday, September 10,
2019 at 8:40 a.m. ET.
CAR-TCR Summit, September 10 - 13, Boston,
MA.
- David O’Donnell, Director, Technology Operations at Unum
Therapeutics, will present "Managing Leukapheresis for
Autologous Cell Therapies" on Tuesday, September 10,
2019 at 9:00 a.m. ET.
- Ann Ranger, Ph.D., Senior Director, Translational Medicine and
Biomarkers at Unum Therapeutics, will present "Clinical
Pharmacology of a Unique Antibody Coupled T Cell (ACTR) Therapy
Combination Product” on Thursday, September 12, 2019 at 1:00 p.m.
ET.
2nd International Conference on Lymphocyte Engineering
(ICLE), September 13 – 15, London, UK.
- Seth Ettenberg, Ph.D., Chief Scientific Officer at Unum
Therapeutics, will present “Addressing the Challenges of T Cell
Therapies in Solid Tumors” on Friday, September 13, 2019 at 6:50
p.m. BST / 1:50 p.m. EDT in London, United Kingdom.
About Unum Therapeutics
Unum Therapeutics is a clinical-stage biopharmaceutical company
focused on developing curative cell therapies to treat a broad
range of cancer patients. Unum’s novel proprietary technologies
include Antibody-Coupled T cell Receptor (ACTR), an autologous
engineered T-cell therapy that combines the cell-killing ability of
T cells and the tumor-targeting ability of co-administered
antibodies to exert potent antitumor immune responses, and Bolt-On
Chimeric Receptor (BOXR), designed to improve the functionality of
engineered T cells by incorporating a “bolt-on” transgene to
overcome resistance of the solid tumor microenvironment to T cell
attack. Unum has multiple programs in Phase 1 clinical testing,
including ACTR707 used in combination with rituximab in adult
patients with r/r NHL and used in combination with trastuzumab in
adult patients with HER2+ advanced cancer, and ACTR087 used in
combination with the novel antibody SEA-BCMA in r/r multiple
myeloma. Unum’s BOXR1030 program targeting GPC3, an oncofetal
antigen expressed in a variety of tumors including certain liver
and lung cancers, is the first product candidate from the BOXR
platform with preclinical studies underway to support the filing of
an investigational new drug (IND) application. The Company is
headquartered in Cambridge, MA.
Follow Unum Therapeutics on social media:
@UnumRx, and LinkedIn.
Investor Contact:Stephanie Ascher,
212-362-1200stephanie@sternir.com
Media Contact:Lissette Steele,
202-930-4762lsteele@vergescientific.com
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Unum Therapeutics (NASDAQ:UMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024